Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer

Inclusion Criteria:

① Patients with advanced CRC confirmed by pathology or cytology and receiving first-line therapy;② Aged ≥ 18 years old, male or female;③ ECOG score 0-2 points;④ Expected survival ≥ 3 months;⑤ According to RECIST1.1 criteria, at least one detectable lesion;⑥ Voluntarily join the study, sign informed consent, compliance with good cooperation with follow-up.

Exclusion Criteria:

• Combined with other malignant primary tumors;

• Immunohistochemistry/polymerase chain reaction/second-generation sequencingresults suggest MSI-H/dMMR patients;

• Patients with recurrence and metastasis within 6 months after radicaltumor surgery;

• Patients who have previously or are undergoing cancer immunotherapy ;Patients undergoing radiation therapy;

• Pregnant or lactating women; women of childbearing age and theirspouses can not take effective contraceptive measures during andwithin 6 months after the end of clinical study; ⑥ Psychiatricpatients; ⑦ Patients with severe, uncontrolled organic diseaseor infection, such as decompensated heart, lung, kidney failurecaused by intolerance to chemotherapy; ⑧ Patients who havereceived clinical trials of small molecule drugs within 28 daysor received clinical trials of large molecule drugs within 3months; ⑨ Patients who are known to be allergic to or intolerantof study drugs.